PROGYNOVA

Country: Индонезија

Језик: Индонежански

Извор: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

Активни састојак:

ESTRADIOL VALERATE

Доступно од:

BAYER INDONESIA - Indonesia

INN (Међународно име):

ESTRADIOL VALERATE

Дозирање:

2 MG

Фармацеутски облик:

TABLET SALUT GULA

Јединице у пакету:

DUS, 1 BLISTER @ 28 TABLET SALUT GULA

Произведен од:

BAYER WEIMAR Gmbh & Co KG - Germany

Датум одобрења:

2019-03-19

Карактеристике производа

Name of Product/Active ingredient/Dosage form/Version/Date of approval
Progynova/Estradiol valerate/Sugar coated tablet/Deletion Shelf-life
info
1
PROGYNOVA
®
2 MG
SUGAR COATED TABLETS
Important information, please read carefully! COMPOSITION
Each white sugar-coated tablet contains estradiol valerate 2.0 mg. PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Natural and semisynthetic estrogen, plain
ATC Code: G03CA03
Progynova contains the estrogen estradiol valerate, a prodrug of the
natural human 17ß- estradiol.
Ovulation is not inhibited during the use of Progynova, and the
endogenous production of hormones is hardly affected.
During
the
climacteric,
the
reduction
and
finally
loss
of
ovarian
estradiol
secretion
can
result
in
instability
of
thermoregulation, causing hot flushes associated with sleep
disturbance and excessive sweating, and urogenital atrophy
with symptoms of vaginal dryness, dyspareunia and urinary
incontinence. Less specific but often mentioned as part of the
climacteric syndrome are symptoms like anginal complaints,
palpitations, irritability, nervousness, lack of energy and
concentration abilities, forgetfulness, loss of libido and joint and
muscle pain. Hormone replacement therapy (HRT)
alleviates many of these symptoms of estradiol deficiency in the
menopausal woman.
HRT
with
an
adequate
estrogen
dosage
like
in
Progynova
2
mg
reduces
bone
resorption
and
retards
or
halts
postmenopausal bone loss. When HRT is discontinued, bone mass declines
at a rate comparable to that in the immediate
postmenopausal period. There is no evidence that HRT restores bone
mass to premenopausal levels. HRT also has a
positive effect on skin collagen content and skin thickness and can
retard the process of skin wrinkling.
HRT changes the lipid profile. It lowers total cholesterol and
LDL-cholesterol and may increase HDL- cholesterol and
triglyceride levels. The metabolic effects may be counteracted to some
extent by the addition of a progestogen.
The addition of a progestogen to an estrogen replacement regime